ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial

NCT05590455 Phase 2 RECRUITING

Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).

Details

Lead sponsor	ANRS, Emerging Infectious Diseases
Phase	Phase 2
Status	RECRUITING
Enrolment	130
Start date	2023-04-11
Completion	2027-12

Conditions

• Tuberculous Meningitis
• HIV I Infection

Interventions

• Adalimumab Injection

Primary outcomes

• 3-month all-cause mortality — 3 months

Countries

Brazil, Mozambique, Zambia